Somerset Pharmaceuticals, Inc. (Somerset) is a proprietary research and development pharmaceutical company located in Tampa, Florida. Somerset markets Eldepryl® in capsule form for the treatment of patients with late-stage Parkinson's Disease.

Somerset is currently engaged in the clinical development of a selegiline transdermal system for the treatment of several indications, including Alzheimer's Disease, Depression and Parkinson's Disease.

Somerset was formed in 1986, and since 1988 Somerset has been jointly owned by Mylan Laboratories, Inc. (NYSE:MYL) and Watson Pharmaceuticals, Inc. (NYSE:WPI).